Skip to main content

Table 5 Association of combined Ki-67 and Her2 expression with pTNM stage in patients with non-metastatic gastric cancer estimated using univariable and multivariable-adjusted logistic regression

From: Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study

Ki-67 and Her2 expression

Overall cancer

Node-negative cancer

Node-positive cancer

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

Univariable testa

 Her2 negative and Ki-67 negative

1 (reference)

 

1 (reference)

 

1 (reference)

 

 Her2 negative and Ki-67 positive

0.70 (0.38–1.30)

0.500

0.11 (0.02–0.54)

0.009

0.99 (0.45–2.17)

0.109

 Her2 positive and Ki-67 negative

0.43 (0.17–1.06)

0.233

0.13 (0.02–0.84)

0.033

0.48 (0.14–1.59)

0.445

 Her2 positive and Ki-67 positive

0.48 (0.22–1.05)

0.337

0.14 (0.02–0.83)

0.038

0.39 (0.15–1.05)

0.122

Multivariable testb

 Her2 negative and Ki-67 negative

1 (reference)

 

1 (reference)

 

1 (reference)

 

 Her2 negative and Ki-67 positive

0.84 (0.44–1.60)

0.807

0.07 (0.01–0.56)

0.025

1.27 (0.55–2.94)

0.126

 Her2 positive and Ki-67 negative

0.64 (0.24–1.70)

0.508

0.05 (< 0.01–0.69)

0.030

0.66 (0.17–2.55)

0.632

 Her2 positive and Ki-67 positive

0.76 (0.33–1.75)

0.838

0.06 (0.01–0.63)

0.026

0.55 (0.19–1.63)

0.266

  1. Significant associations are shown in italics
  2. pTNM stage pathological tumor-node-metastasis stage, Her2 human epidermal growth factor receptor 2, OR odds ratio, CI confidence interval
  3. aPerformed using univariable logistic regression
  4. bPerformed using multivariable logistic regression with adjustment for age, sex, tumor location, length, and differentiation grade